This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The press adds further capacity and high quality color capability to the already well equipped facility which specializes in the production of folded cartons for the pharmaceutical sector.
Kevin Kenjarski, VP of Sales & Marketing at Clondalkin Pharma and Healthcare North America said; “As a forward thinking and customer focused business, investment in equipment that provides our customers access to the best quality products is of paramount importance to us. In the past six years we have invested $300 million in our Pharma and Healthcare packaging business, to drive our customer service capabilities. We offer our customers the most comprehensive network of accredited plants with 17 production sites in North America and Europe. All of these plants are well invested and are leading standard setters for the industry offering distinctive innovation and service capabilities. Working together, the extensive production network promotes specialization and development of excellence centers to ensure best practice delivery every time. ”
The Charlotte facility produces best in class folded cartons to a customer base requiring pharmaceutical and healthcare secondary packaging with the latest brand security, sustainability and structural design solutions.
With annual sales of over $1 billion, Clondalkin Group operates in a wide range of packaging product sectors across international markets with over 40 production facilities in Europe and North America.
The Pharmaceutical and Healthcare division is a global supplier of printed components dedicated to producing cartons, labels and literature that fully comply with cGMP guidelines. An international footprint of 17 facilities, with 9 in North America, means Clondalkin Pharma & Healthcare is uniquely equipped to supply packaging solutions internationally to the highest quality standards with all the added benefits of local responsiveness and service.